Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AstraZeneca
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medully Thyroid Cancer
To assess the objective response rates (ORR) for 150 mg and 300 mg/day of vandetanib in patients with advanced & progressive MTC. ORR = % of patients with a best response of complete or partial respon...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
AstraZeneca
Update Il y a 4 ans
Étude ADAURA : étude de phase 3 randomisée comparant l’efficacité et la sécurité de l’osimertinib (AZD9291) avec celles d’un placebo chez des patients ayant un cancer du poumon non à petites cellules de stade IB-IIIA avec mutation de l’EGFR. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Le cancer du poumon se développe à partir de cellules situées dans le poumon qui se multiplient de manière anormale pour former une masse ou tumeur. Le cancer du poumon non à petites cellules est le t...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
Ensayo fase I/II, abierto, multicéntrico, de AZD2281 oral en combinación con Cisplatino, para valorar la seguridad y tolerabilidad en pacientes con tumores sólidos avanzados, y para valorar la eficacia como terapia neoadyuvante en pacientes con cáncer de mama triple negativo A Phase I/II, Open Label, Multi-centre Study of AZD2281 Administered Orally in Combination with Cisplatin, to Assess the Safety and Tolerability in Patients with Advanced Solid Tumours, and to Assess Efficacy in the Neoadjuvant Setting for Patients with Triple Negative Breast Cancer
Primary objective: · Part A/Phase I: The primary objective is to determine the safety and tolerability of twice daily oral doses of AZD2281 when administered in combination with cisplatin to patients...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. capecitabine (Xeloda) in Patients with Advanced or Metastatic Pancreatic Cancer, who have Failed First Line gemcitabine Therapy (Gemzar)
The primary objective of this study is to assess the efficacy of AZD6244 versus capecitabine in the treatment of advanced or metastatic pancreatic cancer by assessment of time to death (TTD).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
AstraZeneca
Update Il y a 4 ans
Étude HUDSON : étude de phase 2 évaluant l’efficacité, la sécurité d’emploi et la tolérance de plusieurs associations de traitementsa chez des patients ayant un cancer du poumon non à petites cellules métastatique ayant progressé pendant une immunothérapie à base d’anti-PD-1/PD-L1. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
Le cancer du poumon non à petites cellules (CBNPC) est le type de cancer du poumon le plus fréquent, représentant 85 à 90 % de l’ensemble des cas de cancer du poumon. Certaines cellules cancéreuses o...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A comparison of Symbicort® Maintenance and Reliever Therapy (Symbicort Turbuhaler® 160/4.5 mg, one inhalation bid plus as-needed) and Symbicort Turbuhaler 160/4.5 mg, one inhalation bid plus terbutaline Turbuhaler 0.4 mg/inhalation as needed, for treatment of asthma – a 12-month, randomized, double-blind, parallel group, active-controlled, multinational phase III study in asthmatic patients aged 16 years and above
The primary objective of this study is to compare the efficacy of Symbicort® Maintenance and Reliever Therapy (SMART) (Symbicort Turbuhaler® 160/4.5μg, one inhalation bid plus as needed) with Symbicor...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A double-blind, placebo controlled, randomized, two centre phase IIa pharmacodynamic cross-over study to assess the effect of AZD3355, 65 mg bid, on transient lower esophageal sphincter relaxations (TLESRs) in GERD patients with incomplete response to PPI
The primary objective of this study is to assess the effect of repeated oral administration of AZD3355, 65 mg bid, measured as reduction in the number of transient lower esophageal sphincter relaxatio...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sensitivity in GERD patients with a partial response to PPI treatment
The primary objective of the study is to compare a single dose of AZD1386 to placebo on esophageal sensitivity to thermal stimuli 1.5 hours post dose in GERD patients who are partial responders to PPI...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
An Open-Label Extension Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects Ages 1 to <11 Years: A Long Term Study
To describe the long-term clinical experience of candesartan cilexetil in hypertensive children ages 1 to <11 years who have completed Protocol 328 (D2451C00002) and who have an ongoing clinical indic...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
Safety, Tolerability and Efficacy of Ceftaroline in Babies with Late-Onset Sepsis
To evaluate the safety and tolerability of ceftaroline for the treatment of Late-onset sepsis in neonates and young infants aged 7 to <60 days
Country
None
organs
None
Specialty
None
unknown
More information
Previous
12
13
14
15
16
17
18
19
20
21
Next